Warning You have reached the maximum number of saved studies Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome NAS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : August 15, Study Description. The purpose of the study is to determine whether buprenorphine is a beneficial, safe, cost effective treatment alternative to morphine sulfate in the treatment of Neonatal Abstinence Syndrome NAS.
Detailed Description:. Neonatal abstinence syndrome is a condition that affects newborns who are exposed to chronic opioid drugs while they are in a mother's uterus womb prior to birth. The current standard of care treatment includes morphine sulfate. Buprenorphine is a drug used in adults to treat narcotic dependence and withdrawal, but has not yet been approved for use in newborns as a treatment alternative for Neonatal Abstinence Syndrome.
This investigation is designed to measure if sublingual under the tongue buprenorphine is able to reduce hospital length of stay and decrease number of days of drug treatment currently required in treatment of NAS. Another goal will be to understand buprenorphine as a cost effective treatment for NAS. FDA Resources. Arms and Interventions. Sublingual Buprenorphine The injectable formulation of buprenorphine Buprenex; Reckitt Benckiser will be prepared to a final concentration of 0.
Outcome Measures. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol ; 1 : 29 — Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth ; 94 6 : — Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth ; 96 5 : — Clinical pharmacology of buprenorphine: Ceiling effects at high doses.
Clin Pharmacol Ther ; 55 5 : — Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology ; 1 : 51 — 7. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol ; 59 3 : — Ding Z , Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol ; 5 : — Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence.
J Clin Endocrinol Metab ; 90 1 : — 6. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. Postgrad Med ; 1 : 55 — Pattinson KT. Opioids and the control of respiration. Br J Anaesth ; 6 : — Desmetramadol has the safety and analgesic profile of tramadol without its metabolic liabilities: Consecutive randomized, double-blind, placebo- and active comparator-controlled trials.
Dean L. Codeine therapy and CYP2D6 genotype. Medical Genetics Summaries. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol ; 60 4 : — Treatment of chronic pain with various buprenorphine formulations: A systematic review of clinical studies. Anesth Analg ; 2 : — Buprenorphine transdermal system in adults with chronic low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase.
Clin Ther ; 32 5 : — Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: Results of a retrospective cohort study. Clin Ther ; 27 7 : — Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry ; 3 : — 9. Opioids, respiratory depression, and sleep-disordered breathing. Best Pract Res Clin Anaesthesiol ; 31 4 : — Basic Clin Pharmacol Toxicol ; 2 : — 9.
Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol ; 33 2 : — Brandt J , Leong C. Benzodiazepines and z-drugs: An updated review of major adverse outcomes reported on in epidemiologic research.
Lintzeris N , Nielsen S. Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans' Health Administration patients.
Pain Med ; 16 8 : — Pregabalin and the risk for opioid-related death: A nested case-control study. Ann Intern Med ; 10 : — 4. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.
PLoS Med ; 14 10 : e Risk factors for serious prescription opioid-induced respiratory depression or overdose: Comparison of commercially insured and Veterans Health Affairs populations. Pain Med ; 19 1 : 79 — Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med ; 6 6 : — Weighing the risks and benefits of chronic opioid therapy. Am Fam Physician ; 93 12 : — Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.
Neuropsychopharmacology ; 28 11 : — 9. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care ; 41 2 : — Case series of successful postoperative pain management in buprenorphine maintenance therapy patients.
Anesth Analg ; 5 : — Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or naltrexone maintenance therapy. Anesthesiol Clin ; 36 3 : — Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol ; 10 6 : — An observational study of buprenorphine treatment of the prescription opioid dependent pain patient. Am J Addict ; 24 4 : — American Society of Addiction Medicine.
Kornfeld H , Reetz H. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: A review of the literature and demonstration in three chronic pain patients treated with butrans. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Editor's Choice. PRA Health Sciences.
Tel: ; E-mail: websterlynn prahs. Oxford Academic. References G. Das Punshi, M. Hamid, and M. View at: Google Scholar C. Brasher, B. Gafsous, S. Dugue et al. Schultz-Machata, M. Weiss, and K. Vicencio-Rosas, M. Perez-Guille, C. Flores-Perez, J. Trujillo-Jimenez, and J. Kulshrestha and S. View at: Google Scholar E. Michel and B. Howick, I. Chalmers, P. Glasziou et al. Julian and D. View at: Google Scholar J. Higgins, D. Altman, P. Gotzsche et al. Hamunen, K.
Olkkola, and E. Maunuksela, R. Korpela, and K. Olkkola, M. Leijala, and E. Garra, A. Singer, B. Taira et al. White, A. Hodge, R. Vlok, G. Hurtado, K. Eastern, and T. An, M. Binks, T. Melhuish, and L. View at: Publisher Site Google Scholar. More related articles. Download other formats More. Related articles. Single dose.
0コメント